{"Clinical Trial ID": "NCT00296036", "Intervention": ["INTERVENTION 1:", "Urea/Lacic acid creme", "Patients receive urea/lactic acid topical cream applied to the palms and soles twice daily.", "INTERVENTION 2:", "- Placebo cream", "Patients receive a placebo cream applied to the palms and soles twice a day."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Histologically confirmed breast and/or other cancers", "During first treatment with capecitabine as adjuvant therapy (including neoadjuvant) OR for metastatic disease", "When receiving a dose of capecitabine of 2,000 mg/day (1,000 mg twice daily) OR 2,500 mg/day for 14 days with 4 treatments at 3 weeks intervals (+/- 3 days)", "Status Hormone-receptor unspecified", "CHARACTERISTICS OF PATIENTS:", "Men or women", "\u2022 Menopausal status not specified", "No allergy to cream containing urea", "No pre-existing neuropathy grade 2", "No other dermatological conditions, which, in the opinion of the physician, may affect the hands or feet or may complicate the assessment during the study treatment", "THERAPE PRIOR CONCURENT:", "No other competing agent that works to prevent palmar-plant erythrodysaesthesia caused by capecitabine or topical agents in the hands or feet for other indications (e.g. drought)", "No concomitant vitamin B6 > 50 mg/day", "No concomitant or intended use of over-the-counter products containing urea or lactic acid, including any of the following:", "- Aqua Care\u00ae", "\u2022 Medicated Calamine \u00ae lotion (0.3%)", "Coppertone^\u00ae Waterproof Ultra Protection Sunblock", "D. Scholl's^\u00ae Deep moisturizing cream to smooth touch", "- Depicure^\u00ae Cream so smooth", "Dove^\u00ae Wash moisturizing cream", "\u00ae Moisturizing cream", "\u2022 Vaseline Intensive Care ^ \u00ae lotion"], "Results": ["Performance measures:", "To determine whether the prophylactic use of a topical urea/lactic acid cream can reduce the incidence/ severity of palmanr-plantar erythrodysaesthesia caused by capecitabine", "A self-reported hand foot syndrome (HFSD), also known as palmar-plantar erythrodysaesthesia, was completed daily during the application of the cream. Patients assessed the symptoms of skin severity individually in their hands and feet. The definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CCTAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in the hands or feet were tabulated and percentages were reported.", "Duration: first 3 weeks of treatment", "Results 1:", "Title of the arm/group: Urea cream/lactic acid", "Description of the arm/group: Patients receive urea/lactic acid topical cream applied to the palms and soles twice daily.", "Total number of participants analysed: 59", "Type of measurement: Number", "Unit of measure: percentage of participants 13.6", "Results 2:", "Title of the arm/group: Placebo cream", "Description arm/group: Patients receive a placebo cream applied to the palms and soles twice a day.", "Total number of participants analysed: 49", "Type of measurement: Number", "Unit of measure: percentage of participants 10.2"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/67 (0.00 per cent)", "Adverse Events 2:", "Grand total"]}